[{"id":"765f2541-173b-4065-9341-271ee1c9c7bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03984968","created_at":"2021-01-18T19:35:54.233Z","updated_at":"2024-07-02T16:35:16.090Z","phase":"Phase 1/2","brief_title":"CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03984968","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ssCART-19"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-06"},{"id":"dd02312e-952b-4faa-87f6-477dc963725b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04825496","created_at":"2021-04-01T16:52:25.144Z","updated_at":"2024-07-02T16:35:36.211Z","phase":"Phase 1","brief_title":"Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04825496","lead_sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • ssCART-19"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/09/2021","start_date":" 04/09/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-21"}]